Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Menicon CoFRA:5FR -1.58%82 Equity-to-Asset is 0.47 as of Jun. 2026, which is 6% below its 10-year median of 0.50. GuruFocus rates FRA:5FR with a GF Score™ of 82/100 and a GF Value™ of €9.51. The stock has 3 warning signs investors should review. Among 852 Medical Devices & Instruments companies, Menicon Co ranks worse than 70.07% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Menicon Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was €517.6 Mil. Menicon Co's Total Assets for the quarter that ended in Jun. 2026 was €1,094.4 Mil.
Therefore, Menicon Co's Equity to Asset Ratio for the quarter that ended in Jun. 2026 was 0.47.
The historical rank and industry rank for Menicon Co's Equity-to-Asset or its related term are showing as below:
FRA:5FR'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.46 Med: 0.5 Max: 0.61
Current: 0.47
During the past 13 years, the highest Equity to Asset Ratio of Menicon Co was 0.61. The lowest was 0.46. And the median was 0.50.
FRA:5FR's Equity-to-Asset is ranked worse than 70.07% of 852
companies
in the Medical Devices & Instruments industry
Industry Median: 0.64
vs FRA:5FR: 0.47
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Menicon Co Equity-to-Asset Related Terms
Menicon Co Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Menicon Co's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5FR vs ISRG, BDX, RMD: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Menicon Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Menicon Co Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Menicon Co's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Menicon Co's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Menicon Co's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Menicon Co (FRA:5FR) has a Equity-to-Asset of 0.47 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Menicon Co and its competitors. This is near median its historical median of 0.50. Over the past decade, Menicon Co's Equity-to-Asset has ranged from 0.46 to 0.61. According to the industry distribution chart, Menicon Co ranks #597 out of 852 companies in the Medical Devices & Instruments industry, placing it in the top 70.1%.
Is Menicon Co's Equity-to-Asset too high?
Menicon Co's current Equity-to-Asset of 0.47 is near median its 10-year median of 0.50. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 0.61. The Medical Devices & Instruments industry median Equity-to-Asset is 0.64. Menicon Co's value of 0.47 is 26.6% below this industry median. Based on the distribution chart, Menicon Co ranks #597 out of 852 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Menicon Co has a GF Score™ of 82/100, reflecting its overall financial health beyond just this single metric.
How does Menicon Co's Equity-to-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Menicon Co ranks #597 out of 852 companies for Equity-to-Asset. This places Menicon Co in the lower half of its industry. The industry median Equity-to-Asset is 0.64. Menicon Co's value of 0.47 is 26.6% below this benchmark. Historically, Menicon Co's own Equity-to-Asset has ranged from 0.46 to 0.61 over the past decade. While the company's 10-year median is 0.50 vs. the industry median of 0.64, Menicon Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.64, based on 852 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Menicon Co's current Equity-to-Asset of 0.47 is 26.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Menicon Co and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Menicon Co's current Equity-to-Asset is 0.47, which is near median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Menicon Co stock overvalued right now?
Menicon Co (FRA:5FR) has a current Equity-to-Asset of 0.47. The stock's GF Value™ is €9.51, compared to a current price of €9.35 — trading 1.7% below its estimated fair value. The current Equity-to-Asset is 0.47, which is near median its 10-year median of 0.50 and 26.6% below the Medical Devices & Instruments industry median of 0.64. Menicon Co's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Menicon Co (FRA:5FR), the current Equity-to-Asset is 0.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Menicon Co (FRA:5FR) Overvalued in 2026?
Based on GuruFocus' analysis, Menicon Co stock appears to be undervalued.
The current stock price of €9.35 is trading 1.7% below its estimated GF Value™ of €9.51.
Key valuation signals for FRA:5FR:
Equity-to-Asset: 0.47 (near median its 10-year median of 0.50)
GF Value™: €9.51 vs. price of €9.35 (1.7% below fair value)
Industry Position: 26.6% below the Medical Devices & Instruments median (#597 of 852)
No single metric tells the full story. See the FRA:5FR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Menicon Co Ltd is a contact lens manufacturing company. It is involved in manufacturing, sales, export, and import of contact lenses and other medical goods, manufacturing and sales of medical instruments, sales of medical supplies and research and development of intraocular lenses. The firm's products include soft lenses, gas permeable lenses and lens care products.
82GF Score
Get the complete analysis for FRA:5FR
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5FR has been successfully added to your 
